irx-2
Biologicalexperimental
Clinical trial activity
8 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00210470)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 1
- Esophageal Neoplasms · Phase 1/Phase 2
- Liver Neoplasms · Phase 1
- Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Vulvar Neoplasms · Phase 2
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594479 ↗
Also known as
- irx 2
- irx-2
- irx-2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04373031 | Phase 2 | Jul 15, 2020 | Brooklyn Immunotherapeutics, Merck, Providence Health & Services |
| NCT03575234 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2019 | Bristol-Myers Squibb, Brooklyn Immunotherapeutics, Emory University |
| NCT03918499 | Phase 1/Phase 2 (Phase 2) | Apr 18, 2019 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03758781 | Phase 1 | Feb 5, 2019 | University of South Florida |
| NCT03655002 | Phase 1 | Dec 15, 2018 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03267680 | Phase 2 | Nov 8, 2017 | Brooklyn Immunotherapeutics, National Cancer Institute (NCI), University of Southern California |
| NCT02609386 | Phase 2 | Dec 1, 2015 | IRX Therapeutics, University of Michigan |
| NCT00210470 | Phase 2 | Jul 1, 2005 | IRX Therapeutics, University of Michigan |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Brooklyn Immunotherapeutics | For profit | 3 | 0 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2017 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 2 | 2 | 2018 |
| IRX Therapeutics | For profit | 2 | 2 | 1 | 2005 |
| University of Michigan | Academic/Hospital | 2 | 0 | 1 | 2005 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2019 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2020 |
| Providence Health & Services | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2019 |
11 organizations
Page 1 / 1